An interventional study of Collaborative care pathways group and Control group without intervention in Steatotic Liver Disease and Fibrosis of Liver, sponsored by Hospices Civils de Lyon. Not yet recruiting at 10 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-03.
Sponsored by Hospices Civils de Lyon · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 95 studies in Liver Cirrhosis with a site in France — 22 open to participants now, 25 under way, 2 of them phase 3. Liver Cirrhosis · France.
Among the 95 studies in Liver Cirrhosis with a site in France, this one is the 4th largest by planned enrollment of the 53 interventional ones that give a count, is one of 5 that started in 2026, is one of 29 with no phase, reaches primary completion later than 19 of the 24 other live ones, and was the 90th registered.
1,303 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.
Browse Liver Cirrhosis studies →22 of the 95 studies in Liver Cirrhosis with a site in France are open now. Recruiting first, the newest first:
University Medical Center Groningen · Sites in France, Austria, Belgium and 9 more countries
Ages 18+
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18+
University Hospital, Grenoble · Sites in France
Ages 18+
University Hospital, Angers · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nice · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
95 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 16 · Phase 3 10
First in 2002; this study’s year is marked. 5 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 1,714 is above the median of 78 across 742 interventional studies indexed under Liver Cirrhosis.
Median enrollment 205 across the 53 interventional studies, 227 across the 41 observational. Of the 63 that completed or were terminated, 11 (17%) have results posted.
This tab as a report to print or save as PDF → With an account.
27 of 95 have an industry lead sponsor. The 10 most frequent:
Hospices Civils de Lyon is the lead sponsor of 1,868 studies on the registry; 447 are open to participants now.
Hospices Civils de Lyon has 5 studies filed under Liver Cirrhosis — fewer than ten, so there is no comparison to draw.
8 of the studies in Liver Cirrhosis with a site in France that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05500222Phase 3Madrigal Pharmaceuticals, Inc.A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES) | 2026-12 |
| NCT04530760University Hospital, LilleIntraabdominal Hypertension and Occurrence of Microaspiration in Cirrhotics Under Mechanical Ventilation | 2026-12 |
| NCT07585890University Medical Center GroningenEstablishing a Reference Framework for Outcomes After Machine-Preserved Liver Transplantation in Europe | 2026-12-31 |
| NCT04613921European Foundation for Study of Chronic Liver FailureLiver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | 2026-12-31 |
| NCT07439939Assistance Publique - Hôpitaux de ParisExploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Placement | 2027-06-09 |
Add all 8 to your calendar (.ics) → With an account.
Among the 95 studies in Liver Cirrhosis with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 25% of the global adult population, 25-30% of whom suffer from metabolic dysfunction-associated steatohepatitis (MASH), increasing the risk of progression to advanced fibrosis (AF) (fibrosis stage F3 or cirrhosis F4). Screening for AF is justified because it is associated with an increased risk of overall, hepatic, and cardiovascular mortality and therefore constitutes a public health issue.
Patients with type 2 diabetes (T2D) are identified as a priority target for screening because they are at high risk of AF related to MASLD. The recommendations of the French Association for the Study of the Liver 2020 (afef.asso.fr), the European Association for the Study of the Liver (2024), the American Association of Clinical Endocrinology (2022), and the American Association of Diabetes (2025) all recommend a two-step screening process involving the FIB-4 biological score, followed by transient elastography (TE) if the FIB-4 score is > or = 1.30. Finally, if the TE is ≥8 kPa, the patient is considered to be at intermediate/high risk of AF requiring specialized care to confirm the diagnosis and implement appropriate management, including semi-annual screening for hepatocellular carcinoma in cases of cirrhosis Despite these recommendations, their application in clinical practice remains difficult and requires multidisciplinary collaboration between diabetologists and hepatologists, and between community and hospital sectors, particularly to access TE measures.
Since 2018, the Lyon Sud diabetes department (Hospices Civils de Lyon) has implemented an in-hospital AF screening program using TE for T2D patients. However, this screening by private diabetologists has not yet been implemented, mainly due to the lack of a standardized care pathway and difficulty in accessing TE measurements.
HYPOTHESIS The implementation of systematic and standardized AF screening in private diabetes practices, in two stages and using ET in diabetes care in accordance with recommendations, would significantly increase the identification of patients with AF and thus improve their access to specialized services and appropriate care.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Collaborative development of a care pathway for the implementation of a systematic and standardized screening for hepatic AF in patients with T2D in private diabetes clinics. The care pathway will include calculation of the FIB-4 score and transient elastography measurement performed in diabetes clinics if FIB-4≥1.30, in accordance with the recommendations of the French Association for the Study of the Liver (AFEF) and the European Association for the Study of the Liver (EASL).
Procedure: Collaborative care pathways group
Current clinical routine practice with no specific intervention
Procedure: Control group without intervention
CO-CONSTRUCTION OF THE CARE PATHWAY: Participatory approach according to scientific literature, professional practices, and experience of both healthcare providers and patients. Establishment of a working group (hospital endocrinologists, hepatologists, private practice diabetologists, representatives of patients with diabetes followed in the participating centers) to define implementation modalities, professional training, communication and information transfer between professionals, and to ensure a smooth care pathway without overloading the health system . IMPLEMENTATION: Definition of patient care pathway Training of private diabetologists to integrate FIB-4 and TE measurement into their practices Provision of the FibroScan® Monitoring of patients included in the screening program and of the number of TE measurements performed Validation of TE measurements ≥ 8 kPa in a specialized center Definition of referral procedures for patients towards the specialized center
Hepatic AF screening in patients with T2D in private diabetes clinics according to routine care
Proportion of T2D patients eligible for screening and having undergone AF screening according to the recommendations including assessment of the FIB-4 score, measurement of TE if indicated, and referral for specialized care if required
1. Calculation of the FIB-4 score \<1.30 (automatic calculation by the medical analysis laboratory or calculated by the liberal diabetologist). 2. Calculation of the FIB-4 score ≥ 1.30 (automatic calculation by the medical analysis laboratory or calculated by the liberal diabetologist) and realization of a measurement of hepatic TE with either: * TE measurement less than 8 kPa OR * Measurement of TE greater than or equal to 8kPa and referral for specialized care to a private hepatologist, a hospital hepatology department or the Institute of Hepatology of Lyon at HCL According to the recommendations of the EASL (European Association for the Study of the Liver) and the AFEF (French Association for the Study of the Liver), screening includes both the calculation of the FIB-4 score, a transient (TE) measurement, and referral, if indicated, for specialized care. ET and FIB-4 measurements cannot be separated
Time frame: Between 6 and 12 months following inclusion
Proportion of patients undergoing transient elastography (TE) measurement
measurement among patients with a FIB-4 score ≥ 1.3, as documented in medical records
Time frame: Between 6 and 12 months following inclusion
Proportion of patients referred for specialized consultation for the management of MASLD
This include referral to a private hepatologist, a hospital-based hepatology department, or the Hepatology University Hospital Institute (IHU) of Lyon at the Hospices Civils de Lyon (HCL), among those identified through screening
Time frame: Between 6 and 12 months following inclusion
Proportion of patients with TE values ≥ 8 kPa among those referred to specialized care.
Time frame: Between 6 and 12 months following inclusion
Time interval between successive steps of the screening pathway: FIB-4 assessment, TE measurement, and specialized consultation for the management of MASLD.
Time frame: Between 6 and 12 months following inclusion
Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE),
Statement of discontinuation under study.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients refusing the screening process
Follow-up data
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients eligible for the pathway.
Number of patients included in the care pathway.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.
Interviews with patients
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Patient perceptions of their participation in the implementation of the new care pathway
Interviews with patient's perception of risk, uncertainty, anxiety induced by screening).
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.
% of patients with a compliant care pathway
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Transferability of the intervention according to ASTAIRE criteria : characteristics of the target population
ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 1 = Typology of the included population : collection and assessment of descriptive data on the population during the initial assessment
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.
Unreliable TE measurements
Unreliable TE measurements are defined by IQR/Median ratio ≥0,30. Results will be expressed in number of unreliable measurements
Time frame: 2 months after inclusion (strategy implementation period)
Description of the screening pathway (organization, care trajectory, professional training, patient information and education materials)
Time frame: 10 months
Proportion of screening compliance among patients with type 2 diabetes (T2D) included in the study (Follow-up period for maintaining the care pathway)
Time frame: Between 6 and 12 months following inclusion
Number of diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)
Time frame: Between 6 and 12 months following inclusion
Incremental cost-effectiveness ratio (ICER) of implementing a new screening pathway for AF on patients with type 2 diabetes followed in private diabetology practices, compared with usual care
The outcome measure will be the rate of screenings compliant with the recommendations. The ICER will be interpreted as the additional cost generated by the new screening pathway per additional patient screened
Time frame: Over a 12-month period
Net budget impact
Net budget impact will be assessed in euros for the Mandatory Health Insurance (MHI) at 3 years following the deployment of the new screening strategy for AF in patients with type 2 diabetes managed in private diabetology practices
Time frame: over a 3-year horizon
Transferability according to ASTAIRE criteria: nature of the intervention
ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 3 =Typology of the intervention in terms of defining objectives and planning to collect and assess descriptive elements of implementation
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.
Transferability according to ASTAIRE criteria: contextual environment
ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 2 = Typology of the environment : collection and assessment of descriptive data on the environment during the initial assessment
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.
Transferability according to ASTAIRE criteria: required implementation strategies.
ASTAIRE comprises 23 transferability criteria classified in four categories to analyse the comparability of settings and to facilitate transfer including : Category 4 = Typology of the implementation strategies required . continuously throughout the project cycle, collect information relating to the terms and conditions of support for the transfer
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months.
Inter-observer agreement between measurements performed by diabetologists and by an experienced operator in expert center
Inter-observer agreement between measurements will explore the procedure for implementing TE in private diabetes clinics. Results will be expressed in percentage of concordant measurements
Time frame: Throughout the implementation period up to 2 months after inclusion
Single standardized description of the intervention
The Template for Intervention Description and Replication (TIDIER reporting grid, 12 items, BMJ 2014;348:g1687) will be used. This approach ensures comprehensive and reproducible reporting of all components of the intervention.
Time frame: Throughout the implementation period, an average of 12 months
Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE).
Number of inclusions in the post-implementation phase.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of diabetologists not initially participating in implementing the screening pathway (FIB-4 ± TE).
Percentage of screenings compliant with the recommendations.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients refusing the screening process
Non-realisation of prescribed procedures.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients refusing the screening process
Reasons
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients discontinuing the screening process
Follow-up data.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients discontinuing the screening process
Non-realisation of prescribed procedures.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of patients discontinuing the screening process
Reasons
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Perceived appropriateness according to community-based and hospital-based professionals.
Professionals' perception of the relevance and alignment of the pathway with their needs (interviews).
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.
Interviews with private practitioners.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Barriers and facilitators to the implementation of the pathway at both individual and organizational levels, as reported by community-based practitioners, specialized care providers and patients.
Focus group with specialists from the reference center (diabetologists, endocrinologists, hepatologists)
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.
Description of non-compliances
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.
Modification of the pathway
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Underlying reasons for diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)
Time frame: Between 6 and 12 months following inclusion
Number of diabetologists not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.
Statement of discontinuation under study.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of diabetologists not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.
Number of inclusions in the post-implementation phase.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Number of diabetologists not initially participating not implementing the screening pathway (FIB-4 ± TE), and underlying reasons.
Percentage of screenings compliant with the recommendations.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.
Reasons for delays between procedures.
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Fidelity of the implemented pathway to the predefined specifications, and necessary adaptations.
Patient-professional and interprofessional relationships within the framework of the care pathway (interviews)
Time frame: Through the inclusion period (after implementation of the new care pathway), an average of 7 months
Reasons for diabetologists discontinuing participation in the pathway (Follow-up period for maintaining the care pathway)
Time frame: Between 6 and 12 months following inclusion
Start is estimated for May 2026; primary completion for Mar 2029, 34 months later.
Of 207 non-industry interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 73. This study's planned 34 months is close to that.
Counting every sponsor, half of 216 studies reached it within 32 months; a quarter within 17 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.